GLP-1 Penetration and Demand The market growth of GLP-1 drugs has been driven by the high prevalence and cost burden of obesity and diabetes in the US
It may, in fact, be the signal that every other intervention is ultimately downstream of
Once senescent cells are removed, the downstream benefits continue to develop as: SASP-driven inflammation progressively resolves Stem cell niches, previously suppressed by SASP factors, may reactivate Tissue remodeling and repair processes engage in cleared areas The paracrine senescence cascade (where SASP converts healthy cells to senescent ones) is interrupted In mouse models, improvements in kidney function and physical fitness persisted and in some cases continued to develop during the weeks following treatment cessation (Baar et al., 2017)
Managing sleep disturbances in cirrhosis
Available from: Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, MinnesotaPubMed
References Australian Diabetes Society and Australian and New Zealand College of Anaesthetists